press enter »
placeholder
placeholder

FDA approves Clinuvel's rare genetic disorder treatment, shares at record high

FDA approves Clinuvel's rare genetic disorder treatment, shares at record high

(Reuters) - The U.S. Food and Drug Administration approved Australian drugmaker Clinuvel Pharmaceuticals Ltd’s treatment for a rare inherited disorder that causes skin damage from exposure to light, sending its shares to a record high on Wednesday. The treatment, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria (EPP),

U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment

U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it approved Australian drugmaker Clinuvel Pharmaceuticals Ltd’s treatment for a rare inherited disorder that results in skin damage from exposure to light. The treatment, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria, a painful disorder that causes

U.S. FDA approves Clinuvel Pharma's rare skin disorder treatment

U.S. FDA approves Clinuvel Pharma's rare skin disorder treatment

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Australian drugmaker Clinuvel Pharmaceuticals Ltd’s treatment for a rare inherited disorder that results in skin damage from exposure to light, the agency said. The drug, Scenesse, is an under-the-skin implant that treats erythropoietic protoporphyria, a painful disorder that causes